4D MOLECULAR THERAPEUTICS IN's ticker is FDMT and the CUSIP is 35104E100. A total of 99 filers reported holding 4D MOLECULAR THERAPEUTICS IN in Q4 2022. The put-call ratio across all filers is 0.37 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $13,808,498 | -25.9% | 1,084,721 | +5.2% | 0.17% | -18.0% |
| Q2 2023 | $18,637,362 | +5.0% | 1,031,398 | -0.1% | 0.20% | +1.5% |
| Q1 2023 | $17,752,440 | -18.6% | 1,032,719 | +5.1% | 0.20% | -22.3% |
| Q4 2022 | $21,814,640 | +77.3% | 982,199 | -35.8% | 0.26% | +72.2% |
| Q3 2022 | $12,301,000 | +23.7% | 1,529,958 | +7.4% | 0.15% | +32.5% |
| Q2 2022 | $9,942,000 | -42.6% | 1,424,314 | +24.3% | 0.11% | -25.0% |
| Q1 2022 | $17,321,000 | -29.0% | 1,145,585 | +3.1% | 0.15% | -22.4% |
| Q4 2021 | $24,388,000 | -9.9% | 1,111,579 | +10.8% | 0.20% | -7.5% |
| Q3 2021 | $27,063,000 | +9.1% | 1,003,447 | -2.6% | 0.21% | +13.4% |
| Q2 2021 | $24,800,000 | -45.5% | 1,029,897 | -1.7% | 0.19% | -45.0% |
| Q1 2021 | $45,471,000 | +3.1% | 1,048,189 | -1.5% | 0.34% | -0.6% |
| Q4 2020 | $44,092,000 | – | 1,063,744 | – | 0.34% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| VR Adviser, LLC | 3,000,000 | $38,190,000 | 4.02% |
| Casdin Capital, LLC | 1,033,811 | $13,160,414 | 1.46% |
| BVF INC/IL | 4,007,413 | $51,014,367 | 1.38% |
| Deep Track Capital, LP | 2,778,107 | $35,365,302 | 1.36% |
| Opaleye Management Inc. | 308,500 | $3,927,205 | 1.28% |
| Eagle Health Investments LP | 437,911 | $5,574,607 | 1.23% |
| Novo Holdings A/S | 1,200,000 | $15,276,000 | 1.13% |
| RA Capital Management | 4,163,211 | $52,997,676 | 1.04% |
| VIKING GLOBAL INVESTORS LP | 4,787,914 | $60,950,145 | 0.25% |
| HighVista Strategies LLC | 33,419 | $425,424 | 0.20% |